BioSpace News Archive

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce positive results of OK-201, a non-opioid analgesic drug candidate, delivered topically in a mouse neuropathic corneal pain model demonstrating its potential to treat acute and chronic ocular pain.

Agreement Reached with Suzuken Group Subsidiary Chuo Unyu to Establish Kazo Packaging Center, Further Enabling Premier Japanese CDMO’s Prompt and Reliable Pharmaceutical Contract Manufacturing Services

DIC Corporation has completed investment in Vaxa Technologies Ltd., a biotech startup headquartered in Rosh Pina, Israel, as part of a strategic expansion of DIC businesses around health food and other algae-derived products.

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug QIXLEEF for Tetra’s clinical trial programs.

BioInvent continued to make strong clinical and financial progress in Q1 2021. Positive interim results from the Phase 1/2a study of BI-1206 in B-cell non-Hodgkin’s lymphoma are very encouraging.

In January the company signed an exclusive license agreement with IGM Biosciences, Inc. for birinapant. Medivir received a payment of USD 1 million after signing, which is to be followed by an additional USD 1.5 million when IGM includes birinapant in phase I clinical trials.

XPhyto Therapeutics Corp. is pleased to announce that it has delivered 2,000 of its rapid 25-minute PCR tests to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution.

Continued strong order intake, with the strongest order intake figure for a first quarter in Mentice’s history on the back end of our strongest order intake for a fourth quarter ever.

Core One Labs Inc., is pleased to announce it has entered into a letter of intent, dated April 27, 2021, with Lobe Sciences Ltd. pursuant to which the Company will explore the formation of a joint venture with Lobe involving the sale and distribution of biosynthetic psilocybin.

Amgen announced that it agreed last night with the FDA’s proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized clinical trial to compare the safety and efficacy of LUMAKRAS™ at 960 mg once daily versus a lower daily dose of the drug.